The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty
The Journal of Arthroplasty · 2026-09
DOI: 10.1016/j.arth.2026.09.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2026-09. Verfasst von Sri Tummala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas; Texas A&M College of Medicine, Dallas, Texas. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Nonsteroidal anti-inflammatory drugs, particularly selective cyclooxygenase-2 (COX-2) inhibitors, are foundational to multimodal pain management following primary total hip arthroplasty (THA), but concerns regarding bleeding often limit their use in patients receiving chronic anticoagulation. While data support COX-2 inhibitor safety following total knee arthroplasty in this population, THA-specific evidence remains limited. METHODS: Utilizing a national database, patients undergoing primary THA on chronic anticoagulation between 2015 and 2025 were identified and stratified by postoperative exposure to selective COX-2 inhibitors (celecoxib or meloxicam). Propensity-score matching, which included preoperative anemia and history of acute kidney injury as covariates, balanced demographic and clinical characteristics between groups. The primary outcomes were blood transfusion and readmission at cumulative 30, 90, and 180 days postoperatively. Secondary outcomes included reoperation, periprosthetic dislocation, deep vein thrombosis, pulmonary embolism, acute kidney injury, emergency department utilization, and cumulative opioid use through 180 days. RESULTS: The COX-2 inhibitor use was not associated with elevated rates of transfusion, inpatient readmission, reoperation, periprosthetic dislocation, deep vein thrombosis, acute kidney injury, or emergency department utilization at any time point (all P > 0.05). Pulmonary embolism was directionally lower in the COX-2 cohort, reaching nominal significance at 180 days (risk ratio [RR] 0.46, P = 0.012). The COX-2 inhibitor recipients demonstrated lower cumulative opioid use at 30 days (9.84 versus 17.35%; RR: 0.567, P < 0.001), 90 days (11.89 versus 18.78%; RR: 0.633, P < 0.001), and 180 days (15.33 versus 21.88%; RR: 0.701, P < 0.001) compared with patients not receiving COX-2 inhibitors. CONCLUSIONS: In chronically anticoagulated patients undergoing primary THA, postoperative COX-2 inhibitor use was not associated with increased bleeding, readmission, renal, or surgical complications and was associated with lower cumulative postoperative opioid utilization. These observational findings support cautious COX-2 inhibitor use within multimodal analgesia in this population; however, future prospective studies are warranted to validate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas; Texas A&M College of Medicine, Dallas, Texas.
- Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
Zitieren
APA
Tummala, S., Valencia, A., Chen, A. F., Bounajem, G., & Sambandam, S. N. (2026). The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2026.09.012
Vancouver
Tummala S, Valencia A, Chen AF, Bounajem G, Sambandam SN. The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty. The Journal of Arthroplasty. 2026. doi:10.1016/j.arth.2026.09.012
BibTeX
@article{Tummala2026,
author = {Tummala, Sri and Valencia, Angel and Chen, Antonia F and Bounajem, Georges and Sambandam, Senthil N},
title = {The Safety of Postoperative Selective Cyclooxygenase-2 Inhibitors in Chronically Anticoagulated Patients Undergoing Primary Total Hip Arthroplasty},
journal = {The Journal of Arthroplasty},
year = {2026},
doi = {10.1016/j.arth.2026.09.012}
}
EUVIMED